HBIO (Harvard Bioscience) Institutional Ownership: 36.89% (As of Sep. 06, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HBIO Harvard Bioscience Inc HBIO
53 GF Score
Price $8.06
GF Value $12.30
Valuation Possible Value Trap
! 9 Warning Signs
View Full Analysis

What is Harvard Bioscience Institutional Ownership?

Harvard Bioscience HBIO 53 Institutional Ownership is 36.89% as of Sep. 06, 2026. GuruFocus rates HBIO with a GF Score™ of 53/100 and a GF Value™ of $12.30 (Possible Value Trap). The stock has 9 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Harvard Bioscience's institutional ownership is 36.89%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Harvard Bioscience's Insider Ownership is 27.95%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Harvard Bioscience's Float Percentage Of Total Shares Outstanding is 98.41%.

Harvard Bioscience Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Harvard Bioscience's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Harvard Bioscience Institutional Ownership Chart

Harvard Bioscience Historical Data

The historical data trend for Harvard Bioscience can be seen below:

2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30 2026-07-31 2026-08-31
Institutional Ownership 16.77 11.41 11.35 11.35 11.30 11.31 11.26 11.69 12.54 12.64
HBIO
53GF Score
Harvard Bioscience Inc HBIO
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Harvard Bioscience Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 36.89% mean?
Harvard Bioscience (HBIO) has a Institutional Ownership of 36.89% as of Sep. 06, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Harvard Bioscience and its competitors.
Is Harvard Bioscience's Institutional Ownership too high?
Harvard Bioscience's current Institutional Ownership is 36.89%. Overall, Harvard Bioscience has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Harvard Bioscience's Institutional Ownership compare to MLSS and FEMY?
Harvard Bioscience's Institutional Ownership of 36.89% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Medical Devices & Instruments company?
A good Institutional Ownership depends on the Medical Devices & Instruments industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Harvard Bioscience and its competitors. Harvard Bioscience's current Institutional Ownership is 36.89%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harvard Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Harvard Bioscience (HBIO) is currently considered Possible Value Trap. The stock's GF Value™ is $12.30, compared to a current price of $8.06 — trading 34.5% below its estimated fair value. The current Institutional Ownership is 36.89%. Harvard Bioscience's overall GF Score™ is 53/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Harvard Bioscience (HBIO), the current Institutional Ownership is 36.89% as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harvard Bioscience (HBIO) Overvalued in 2026?

Based on GuruFocus' analysis, Harvard Bioscience stock appears to be undervalued. The current stock price of $8.06 is trading 34.5% below its estimated GF Value™ of $12.30. GuruFocus considers Harvard Bioscience to be Possible Value Trap.

Key valuation signals for HBIO:

  • Institutional Ownership: 36.89%
  • GF Value™: $12.30 vs. price of $8.06 (34.5% below fair value)
  • GF Score™: 53/100 with 9 warning signs

No single metric tells the full story. See the HBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harvard Bioscience Business Description

Address 84 October Hill Road, Suite 10, Holliston, MA, USA, 01746
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
53GF Score

Get the complete analysis for HBIO

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.06
Price
$12.30
GF Value